{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T08:22:18Z","timestamp":1794558138691,"version":"4.9.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the Technological innovation research and development projects of Chengdu Science and Technology Bureau, China under Grant","award":["2022-YF05-01725-SN"],"award-info":[{"award-number":["2022-YF05-01725-SN"]}],"id":[{"id":"https:\/\/ror.org\/00xfea068","id-type":"ROR","asserted-by":"crossref"}]},{"name":"the National Science and Technology Major Projects of New Drugs","award":["2018ZX09201018-013"],"award-info":[{"award-number":["2018ZX09201018-013"]}]},{"name":"the National Science and Technology Major Project for Infectious Diseases Control","award":["2017ZX10203206-004"],"award-info":[{"award-number":["2017ZX10203206-004"]}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81101728"],"award-info":[{"award-number":["81101728"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chimeric antigen receptor (CAR)-T cell therapy has shown success in hematologic malignancies but has encountered challenges in solid tumors. Macrophages, being a potentially effective therapeutic target, have led to the development of several therapeutic strategies due to their unique phagocytic function. This study aimed to develop an effective solid tumor immunotherapy strategy by combining CAR macrophages (CAR-Ms) targeting PD-L1 with CD47 antibody-armed oncolytic adenovirus (oAd-CD47).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this study, an adenoviral vector was employed to construct CAR-Ms that target PD-L1 and express IFN-\u03b3. The phagocytic capacity and phenotype of CAR-Ms were tested in vitro. Two mouse tumor models with different immunogenicity were utilized to investigate the anti-tumor efficacy of CAR-Ms in vivo. Subsequently, the synergistic anti-tumor effects of CAR-M and oAd-CD47 and their underlying mechanisms were explored.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      CAR-Ms exhibited enhanced phagocytic capacity and proinflammatory (M1) phenotype. These CAR-Ms significantly reduced tumor burden and extended overall survival in mice bearing CT26 colon cancer, a model characterized by high immunogenicity. Compared with CAR-Ms and oAd-CD47 monotherapy, this combination therapy (C\u2009+\u2009o) achieved superior antitumor efficacy in the CT26 and B16 melanoma mouse models, as well as in the ID8 peritoneal metastasis model. Notably, C\u2009+\u2009o treatment enhanced tumor-associated macrophage (TAM) phagocytosis and reduced the population of inhibitory immune cell subsets, thereby resulting in enhanced adaptive antitumor T-cell and neoantigen-specific T-cell immunity. Additionally, the synergistic antitumor effect of C\u2009+\u2009o was dependent on CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cells.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The treatment strategy of CAR-Ms combined with oAd-CD47 provides a promising, novel and effective treatment method for individualized targeted therapy of solid tumors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s40164-025-00696-7","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T15:19:54Z","timestamp":1755184794000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["CD47 antibody-armed oncolytic adenovirus promotes chimeric antigen receptor macrophage phagocytosis and antitumor immunity"],"prefix":"10.1186","volume":"14","author":[{"given":"Zhongbing","family":"Qi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shichuan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianglin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anliang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingzhe","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianchuan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,14]]},"reference":[{"issue":"26","key":"696_CR1","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene Ciloleucel CAR T-Cell therapy in refractory large B-Cell lymphoma. N Engl J Med. 2017;377(26):2531\u201344.","journal-title":"N Engl J Med"},{"issue":"4","key":"696_CR2","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.ccell.2020.07.005","volume":"38","author":"M Hong","year":"2020","unstructured":"Hong M, Clubb JD, Chen YY. Engineering CAR-T cells for next-generation cancer therapy. Cancer Cell. 2020;38(4):473\u201388.","journal-title":"Cancer Cell"},{"issue":"5","key":"696_CR3","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439\u201348.","journal-title":"N Engl J Med"},{"issue":"26","key":"696_CR4","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","volume":"377","author":"SJ Schuster","year":"2017","unstructured":"Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak \u00d6, et al. Chimeric antigen receptor T cells in refractory B-Cell lymphomas. N Engl J Med. 2017;377(26):2545\u201354.","journal-title":"N Engl J Med"},{"issue":"4","key":"696_CR5","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11(4):69.","journal-title":"Blood Cancer J"},{"issue":"24","key":"696_CR6","doi-asserted-by":"publisher","first-page":"7168","DOI":"10.1158\/0008-5472.CAN-14-2458","volume":"74","author":"CY Slaney","year":"2014","unstructured":"Slaney CY, Kershaw MH, Darcy PK. Trafficking of T cells into tumors. Cancer Res. 2014;74(24):7168\u201374.","journal-title":"Cancer Res"},{"issue":"5","key":"696_CR7","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1038\/s41423-021-00655-2","volume":"18","author":"G Liu","year":"2021","unstructured":"Liu G, Rui W, Zhao X, Lin X. Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment. Cell Mol Immunol. 2021;18(5):1085\u201395.","journal-title":"Cell Mol Immunol"},{"issue":"9","key":"696_CR8","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/s41577-019-0167-y","volume":"19","author":"G Lemke","year":"2019","unstructured":"Lemke G. How macrophages deal with death. Nat Rev Immunol. 2019;19(9):539\u201349.","journal-title":"Nat Rev Immunol"},{"issue":"12","key":"696_CR9","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1038\/nri2448","volume":"8","author":"DM Mosser","year":"2008","unstructured":"Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol. 2008;8(12):958\u201369.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"696_CR10","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40164-023-00469-0","volume":"13","author":"M Cao","year":"2024","unstructured":"Cao M, Wang Z, Lan W, Xiang B, Liao W, Zhou J, et al. The roles of tissue resident macrophages in health and cancer. Exp Hematol Oncol. 2024;13(1):3.","journal-title":"Exp Hematol Oncol"},{"key":"696_CR11","doi-asserted-by":"crossref","unstructured":"Li C, Xu X, Wei S, Jiang P, Xue L, Wang J. Tumor-associated macrophages: potential therapeutic strategies and future prospects in cancer. J Immunother Cancer 2021;9(1).","DOI":"10.1136\/jitc-2020-001341"},{"issue":"1","key":"696_CR12","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s40164-024-00543-1","volume":"13","author":"S Zheng","year":"2024","unstructured":"Zheng S, Wang W, Shen L, Yao Y, Xia W, Ni C. Tumor battlefield within inflamed, excluded or desert immune phenotypes: the mechanisms and strategies. Exp Hematol Oncol. 2024;13(1):80.","journal-title":"Exp Hematol Oncol"},{"key":"696_CR13","doi-asserted-by":"publisher","first-page":"121137","DOI":"10.1016\/j.biomaterials.2021.121137","volume":"278","author":"GR Gunassekaran","year":"2021","unstructured":"Gunassekaran GR, Poongkavithai Vadevoo SM, Baek MC, Lee B. M1 macrophage exosomes engineered to foster M1 polarization and target the IL-4 receptor inhibit tumor growth by reprogramming tumor-associated macrophages into M1-like macrophages. Biomaterials. 2021;278:121137.","journal-title":"Biomaterials"},{"issue":"1","key":"696_CR14","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13045-023-01473-x","volume":"16","author":"X Cheng","year":"2023","unstructured":"Cheng X, Wang H, Wang Z, Zhu B, Long H. Tumor-associated myeloid cells in cancer immunotherapy. J Hematol Oncol. 2023;16(1):71.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"696_CR15","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13046-022-02327-z","volume":"41","author":"K Pan","year":"2022","unstructured":"Pan K, Farrukh H, Chittepu V, Xu H, Pan CX, Zhu Z. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy. J Exp Clin Cancer Res. 2022;41(1):119.","journal-title":"J Exp Clin Cancer Res"},{"issue":"11","key":"696_CR16","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41573-022-00520-5","volume":"21","author":"A Mantovani","year":"2022","unstructured":"Mantovani A, Allavena P, Marchesi F, Garlanda C. Macrophages as tools and targets in cancer therapy. Nat Rev Drug Discov. 2022;21(11):799\u2013820.","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"696_CR17","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","volume":"38","author":"M Klichinsky","year":"2020","unstructured":"Klichinsky M, Ruella M, Shestova O, Lu XM, Best A, Zeeman M, et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat Biotechnol. 2020;38(8):947\u201353.","journal-title":"Nat Biotechnol"},{"issue":"7637","key":"696_CR18","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature21349","volume":"541","author":"DS Chen","year":"2017","unstructured":"Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541(7637):321\u201330.","journal-title":"Nature"},{"issue":"1","key":"696_CR19","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1002\/med.21727","volume":"41","author":"MA Hossain","year":"2021","unstructured":"Hossain MA, Liu G, Dai B, Si Y, Yang Q, Wazir J, et al. Reinvigorating exhausted CD8(+) cytotoxic T lymphocytes in the tumor microenvironment and current strategies in cancer immunotherapy. Med Res Rev. 2021;41(1):156\u2013201.","journal-title":"Med Res Rev"},{"key":"696_CR20","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","volume":"16","author":"S Bagchi","year":"2021","unstructured":"Bagchi S, Yuan R, Engleman EG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol. 2021;16:223\u201349.","journal-title":"Annu Rev Pathol"},{"issue":"1","key":"696_CR21","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/imr.12527","volume":"276","author":"HL Matlung","year":"2017","unstructured":"Matlung HL, Szilagyi K, Barclay NA, van den Berg TK. The CD47-SIRP\u03b1 signaling axis as an innate immune checkpoint in cancer. Immunol Rev. 2017;276(1):145\u201364.","journal-title":"Immunol Rev"},{"issue":"5","key":"696_CR22","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.cell.2010.07.044","volume":"142","author":"MP Chao","year":"2010","unstructured":"Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B, Gill S, et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell. 2010;142(5):699\u2013713.","journal-title":"Cell"},{"issue":"48","key":"696_CR23","doi-asserted-by":"publisher","first-page":"37984","DOI":"10.1074\/jbc.M002334200","volume":"275","author":"X Han","year":"2000","unstructured":"Han X, Sterling H, Chen Y, Saginario C, Brown EJ, Frazier WA, et al. CD47, a ligand for the macrophage fusion receptor, participates in macrophage multinucleation. J Biol Chem. 2000;275(48):37984\u201392.","journal-title":"J Biol Chem"},{"key":"696_CR24","doi-asserted-by":"publisher","first-page":"897561","DOI":"10.3389\/fonc.2022.897561","volume":"12","author":"B Zhang","year":"2022","unstructured":"Zhang B, Shu Y, Hu S, Qi Z, Chen Y, Ma J, et al. In situ tumor vaccine expressing Anti-CD47 antibody enhances antitumor immunity. Front Oncol. 2022;12:897561.","journal-title":"Front Oncol"},{"issue":"2","key":"696_CR25","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1189\/jlb.0603252","volume":"75","author":"K Schroder","year":"2004","unstructured":"Schroder K, Hertzog PJ, Ravasi T, Hume DA. Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol. 2004;75(2):163\u201389.","journal-title":"J Leukoc Biol"},{"issue":"18","key":"696_CR26","doi-asserted-by":"publisher","first-page":"eaaz6579","DOI":"10.1126\/sciadv.aaz6579","volume":"6","author":"MA Shields CWt, Evans","year":"2020","unstructured":"Shields CWt, Evans MA, Wang LL, Baugh N, Iyer S, Wu D, et al. Cellular backpacks for macrophage immunotherapy. Sci Adv. 2020;6(18):eaaz6579.","journal-title":"Sci Adv"},{"issue":"1","key":"696_CR27","doi-asserted-by":"publisher","first-page":"2688","DOI":"10.1038\/s41467-019-10594-2","volume":"10","author":"AM D\u2019Alise","year":"2019","unstructured":"D\u2019Alise AM, Leoni G, Cotugno G, Troise F, Langone F, Fichera I, et al. Adenoviral vaccine targeting multiple neoantigens as strategy to eradicate large tumors combined with checkpoint Blockade. Nat Commun. 2019;10(1):2688.","journal-title":"Nat Commun"},{"issue":"1","key":"696_CR28","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13045-022-01335-y","volume":"15","author":"Y Wang","year":"2022","unstructured":"Wang Y, Johnson KCC, Gatti-Mays ME, Li Z. Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy. J Hematol Oncol. 2022;15(1):118.","journal-title":"J Hematol Oncol"},{"issue":"3","key":"696_CR29","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.it.2017.12.005","volume":"39","author":"A Veillette","year":"2018","unstructured":"Veillette A, Chen J. SIRP\u03b1-CD47 immune checkpoint Blockade in anticancer therapy. Trends Immunol. 2018;39(3):173\u201384.","journal-title":"Trends Immunol"},{"issue":"10","key":"696_CR30","doi-asserted-by":"publisher","first-page":"e551","DOI":"10.1002\/ctm2.551","volume":"11","author":"S Pisano","year":"2021","unstructured":"Pisano S, Lenna S, Healey GD, Izardi F, Meeks L, Jimenez YS, et al. Assessment of the immune landscapes of advanced ovarian cancer in an optimized in vivo model. Clin Transl Med. 2021;11(10):e551.","journal-title":"Clin Transl Med"},{"issue":"7","key":"696_CR31","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","volume":"14","author":"A Mantovani","year":"2017","unstructured":"Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol. 2017;14(7):399\u2013416.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"696_CR32","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41392-021-00484-9","volume":"6","author":"X Xiang","year":"2021","unstructured":"Xiang X, Wang J, Lu D, Xu X. Targeting tumor-associated macrophages to synergize tumor immunotherapy. Signal Transduct Target Ther. 2021;6(1):75.","journal-title":"Signal Transduct Target Ther"},{"issue":"43","key":"696_CR33","doi-asserted-by":"publisher","first-page":"e2103258","DOI":"10.1002\/adma.202103258","volume":"33","author":"M Kang","year":"2021","unstructured":"Kang M, Lee SH, Kwon M, Byun J, Kim D, Kim C, et al. Nanocomplex-Mediated in vivo programming to chimeric antigen Receptor-M1 macrophages for cancer therapy. Adv Mater. 2021;33(43):e2103258.","journal-title":"Adv Mater"},{"issue":"1","key":"696_CR34","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.molmed.2014.10.009","volume":"21","author":"KC Ohaegbulam","year":"2015","unstructured":"Ohaegbulam KC, Assal A, Lazar-Molnar E, Yao Y, Zang X. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med. 2015;21(1):24\u201333.","journal-title":"Trends Mol Med"},{"issue":"8","key":"696_CR35","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1038\/s41422-018-0060-4","volume":"28","author":"Y Yang","year":"2018","unstructured":"Yang Y, Li CW, Chan LC, Wei Y, Hsu JM, Xia W, et al. Exosomal PD-L1 harbors active defense function to suppress T cell killing of breast cancer cells and promote tumor growth. Cell Res. 2018;28(8):862\u20134.","journal-title":"Cell Res"},{"key":"696_CR36","doi-asserted-by":"crossref","unstructured":"Robbins Y, Greene S, Friedman J, Clavijo PE, Van Waes C, Fabian KP et al. Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells. Elife 2020;9.","DOI":"10.7554\/eLife.54854"},{"key":"696_CR37","doi-asserted-by":"crossref","unstructured":"Bajor M, Graczyk-Jarzynka A, Marhelava K, Burdzinska A, Muchowicz A, Goral A et al. PD-L1 CAR effector cells induce self-amplifying cytotoxic effects against target cells. J Immunother Cancer 2022;10(1).","DOI":"10.1136\/jitc-2021-002500"},{"issue":"5473","key":"696_CR38","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1126\/science.288.5473.2051","volume":"288","author":"PA Oldenborg","year":"2000","unstructured":"Oldenborg PA, Zheleznyak A, Fang YF, Lagenaur CF, Gresham HD, Lindberg FP. Role of CD47 as a marker of self on red blood cells. Science. 2000;288(5473):2051\u20134.","journal-title":"Science"},{"key":"696_CR39","doi-asserted-by":"crossref","unstructured":"Panagiotou E, Syrigos NK, Charpidou A, Kotteas E, Vathiotis IA. CD24: a novel target for cancer immunotherapy. J Pers Med 2022;12(8).","DOI":"10.3390\/jpm12081235"},{"issue":"2","key":"696_CR40","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/cmi.2009.119","volume":"7","author":"X Fang","year":"2010","unstructured":"Fang X, Zheng P, Tang J, Liu Y. CD24: from A to Z. Cell Mol Immunol. 2010;7(2):100\u20133.","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"696_CR41","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13045-023-01492-8","volume":"16","author":"P Zhang","year":"2023","unstructured":"Zhang P, Zhang G, Wan X. Challenges and new technologies in adoptive cell therapy. J Hematol Oncol. 2023;16(1):97.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"696_CR42","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s40164-024-00549-9","volume":"13","author":"J Li","year":"2024","unstructured":"Li J, Chen P, Ma W. The next frontier in immunotherapy: potential and challenges of CAR-macrophages. Exp Hematol Oncol. 2024;13(1):76.","journal-title":"Exp Hematol Oncol"},{"issue":"13Supplement","key":"696_CR43","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1158\/1538-7445.AM2021-63","volume":"81","author":"S Pierini","year":"2021","unstructured":"Pierini S, Gabbasov R, Gabitova L, Ohtani Y, Shestova O, Gill S, et al. Abstract 63: chimeric antigen receptor macrophages (CAR-M) induce anti-tumor immunity and synergize with T cell checkpoint inhibitors in pre-clinical solid tumor models. Cancer Res. 2021;81(13Supplement):63.","journal-title":"Cancer Res"},{"key":"696_CR44","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.jconrel.2023.07.021","volume":"360","author":"Z Yang","year":"2023","unstructured":"Yang Z, Liu Y, Zhao K, Jing W, Gao L, Dong X, et al. Dual mRNA co-delivery for in situ generation of phagocytosis-enhanced CAR macrophages augments hepatocellular carcinoma immunotherapy. J Control Release. 2023;360:718\u201333.","journal-title":"J Control Release"},{"issue":"27","key":"696_CR45","doi-asserted-by":"publisher","first-page":"11103","DOI":"10.1073\/pnas.1305569110","volume":"110","author":"D Tseng","year":"2013","unstructured":"Tseng D, Volkmer JP, Willingham SB, Contreras-Trujillo H, Fathman JW, Fernhoff NB, et al. Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response. Proc Natl Acad Sci U S A. 2013;110(27):11103\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"696_CR46","doi-asserted-by":"crossref","unstructured":"van Duijn A, Van der Burg SH, Scheeren FA. CD47\/SIRP\u03b1 axis: bridging innate and adaptive immunity. J Immunother Cancer 2022;10(7).","DOI":"10.1136\/jitc-2022-004589"},{"issue":"1","key":"696_CR47","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1186\/s12967-023-04479-8","volume":"21","author":"Y Chen","year":"2023","unstructured":"Chen Y, Zhu X, Liu H, Wang C, Chen Y, Wang H, et al. The application of HER2 and CD47 CAR-macrophage in ovarian cancer. J Transl Med. 2023;21(1):654.","journal-title":"J Transl Med"},{"issue":"7385","key":"696_CR48","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/nature10803","volume":"482","author":"M DuPage","year":"2012","unstructured":"DuPage M, Mazumdar C, Schmidt LM, Cheung AF, Jacks T. Expression of tumour-specific antigens underlies cancer immunoediting. Nature. 2012;482(7385):405\u20139.","journal-title":"Nature"},{"issue":"4","key":"696_CR49","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/s41571-020-00460-2","volume":"18","author":"E Blass","year":"2021","unstructured":"Blass E, Ott PA. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat Rev Clin Oncol. 2021;18(4):215\u201329.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"696_CR50","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1038\/s41467-020-15229-5","volume":"11","author":"G Wang","year":"2020","unstructured":"Wang G, Kang X, Chen KS, Jehng T, Jones L, Chen J, et al. An engineered oncolytic virus expressing PD-L1 inhibitors activates tumor neoantigen-specific T cell responses. Nat Commun. 2020;11(1):1395.","journal-title":"Nat Commun"},{"issue":"657","key":"696_CR51","doi-asserted-by":"publisher","first-page":"eabo7604","DOI":"10.1126\/scitranslmed.abo7604","volume":"14","author":"AM D\u2019Alise","year":"2022","unstructured":"D\u2019Alise AM, Brasu N, De Intinis C, Leoni G, Russo V, Langone F, et al. Adenoviral-based vaccine promotes neoantigen-specific CD8 (+) T cell stemness and tumor rejection. Sci Transl Med. 2022;14(657):eabo7604.","journal-title":"Sci Transl Med"},{"issue":"9","key":"696_CR52","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41573-020-0074-8","volume":"19","author":"A Harari","year":"2020","unstructured":"Harari A, Graciotti M, Bassani-Sternberg M, Kandalaft LE. Antitumour dendritic cell vaccination in a priming and boosting approach. Nat Rev Drug Discov. 2020;19(9):635\u201352.","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"696_CR53","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.ccell.2024.02.013","volume":"42","author":"JD Beck","year":"2024","unstructured":"Beck JD, Diken M, Suchan M, Streuber M, Diken E, Kolb L, et al. Long-lasting mRNA-encoded interleukin-2 restores CD8 (+) T cell neoantigen immunity in MHC class I-deficient cancers. Cancer Cell. 2024;42(4):568\u2013e8211.","journal-title":"Cancer Cell"}],"container-title":["Experimental Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-025-00696-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40164-025-00696-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-025-00696-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T04:51:02Z","timestamp":1757393462000},"score":1,"resource":{"primary":{"URL":"https:\/\/ehoonline.biomedcentral.com\/articles\/10.1186\/s40164-025-00696-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,14]]},"references-count":53,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["696"],"URL":"https:\/\/doi.org\/10.1186\/s40164-025-00696-7","relation":{},"ISSN":["2162-3619"],"issn-type":[{"value":"2162-3619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,14]]},"assertion":[{"value":"11 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were performed following the guidelines by the Animal Care and Use Committee of West China Hospital, Sichuan University, China.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"106"}}